Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03422224

ALLoreactive T-Cell receptOr RePertoire in kidnEy tranSplantation — ALL-T-COPIES  

Renal Transplant Rejection Clinical Trial

Official title:
Alloreactive t Cell Repertoire in Kidney Transplantation Recipients

Clinical Trial Summary

In this study, the investigators will establish a workflow to generate unique patterns of the donor-reactive T cell repertoire using mixed lymphocyte reactions to select alloreactive T cell clones prior to transplantation Tissue infiltrating as well as blood bound T cells will be characterized based on: 1. Identification of donor-specific T cell receptor sequences pre- and post-transplant by in vitro expansion to determine unique patterns 2. Quantification and comparison of donor-specific T cell clones in kidney biopsy and blood samples. 3. Analysis of the TCR repertoire diversities derived from kidney biopsy and blood samples and association of repertoire diversities with the histomorphological phenotype of T cell mediated rejection. 4. Identification of T cell subtypes within the donor-reactive population. The investigators specifically hypothesize that highly expanded donor-reactive T cell clones in both kidney tissue and blood samples at time of indication biopsy are associated with the histological phenotype of acute T cell mediated rejection. The investigators have previously shown that there is a strong correlation between highly expanded tissue-resident T cell clones and the repertoire found in periphery blood samples. To trace and quantify donor reactive T cells the investigators will apply a truly quantitative approach for immune repertoire profiling based on high- throughput sequencing. The investigators ultimate goal is to develop a diagnostic tool to assess alloreactive cellular immunoresponses based on peripheral blood samples.

Clinical Trial Description

Kidney transplant recipients receiving a non lymphodepletional induction therapy at the investigators center will be included in this study. Alloreactive T cells are defined prior to transplantation via a mixed lymphocyte reaction of donor and recipient PBMC's. Following transplantation PBMC's will be sampled at management (3 and 12 months) and for-cause biopsies and fifteen patients with histological proven acute T cell mediated rejection will be compared to 15 patients without histopathological signs of alloimmune response in time matched for-cause biopsies. T cell receptor beta chains of T cells found in the circulation and the allograft biopsy will be sequenced via Next generation sequencing. Abundance of alloreactive T cells of the overall repertoire pre-and post-transplant and their presence in the allograft will be assessed. The diversity of the overall repertoire and alloreactive repertoire will be compared between these two groups. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03422224
Study type Observational
Source Medical University of Vienna
Contact Constantin N Aschauer, MD
Phone 00434040043890
Email constantin.aschauer@meduniwien.ac.at
Status Recruiting
Phase
Start date July 1, 2017
Completion date July 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT03140514 - Urine CXCL10 Chemokine Monitoring Post-renal Transplant N/A
Completed NCT02581436 - Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR N/A
Active, not recruiting NCT02409940 - To Elucidate the Effect of Mesenchymal Stem Cells on the T Cell Repertoire of the Kidney Transplant Patients Phase 1
Completed NCT02377193 - Simulect Versus ATG in Sensitized Renal Transplant Patient Phase 4
Completed NCT00771745 - Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients Phase 4
Not yet recruiting NCT05385432 - Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies Phase 3
Completed NCT01953120 - Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309) Phase 4
Terminated NCT01324934 - Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids Phase 3
Terminated NCT00983645 - A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity Phase 4
Active, not recruiting NCT04530630 - Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant Phase 4
Recruiting NCT03707262 - Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor Phase 1/Phase 2
Completed NCT02006108 - Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance N/A
Recruiting NCT03991780 - Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection Phase 1/Phase 2
Completed NCT02733029 - Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection Phase 2
Active, not recruiting NCT02057965 - Mesenchymal Stromal Cell Therapy in Renal Recipients Phase 2
Completed NCT00658073 - Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts N/A
Terminated NCT03646344 - Heme Arginate in Transplantation Study Phase 3
Completed NCT02866682 - Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients Phase 4
Not yet recruiting NCT06438107 - Deep Phenotyping of the Renal Allograft to Prognosticate Clinical Outcomes
Completed NCT02500251 - Belimumab Impacting Transplant Eligibility Phase 1/Phase 2